CML

Key clinical point: Among patients with chronic myeloid leukemia (CML) presenting with COVID-19, better prognosis was observed in patients with controlled disease and those on tyrosine kinase inhibitor (TKI) therapies.

Major finding: Patients with vs without major molecular response had superior overall survival (91% vs 61%; P = .0004). Moreover, patients in treatment-free remission (100%) or on TKI therapy (89%) had higher survival vs patients who underwent hematopoietic stem cell transplantation (50%) or not receiving TKI treatment (33%; P < .001).

Study details: Findings are from an observational study assessing COVID-19 outcomes in 92 patients with CML in Latin America between March and December 2020.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Pagnano KB et al. Leuk Lymphoma. 2021 Jul 13. doi: 10.1080/10428194.2021.1950709.

Key clinical point: Among patients with chronic myeloid leukemia (CML) presenting with COVID-19, better prognosis was observed in patients with controlled disease and those on tyrosine kinase inhibitor (TKI) therapies.

Major finding: Patients with vs without major molecular response had superior overall survival (91% vs 61%; P = .0004). Moreover, patients in treatment-free remission (100%) or on TKI therapy (89%) had higher survival vs patients who underwent hematopoietic stem cell transplantation (50%) or not receiving TKI treatment (33%; P < .001).

Study details: Findings are from an observational study assessing COVID-19 outcomes in 92 patients with CML in Latin America between March and December 2020.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Pagnano KB et al. Leuk Lymphoma. 2021 Jul 13. doi: 10.1080/10428194.2021.1950709.

Key clinical point: Among patients with chronic myeloid leukemia (CML) presenting with COVID-19, better prognosis was observed in patients with controlled disease and those on tyrosine kinase inhibitor (TKI) therapies.

Major finding: Patients with vs without major molecular response had superior overall survival (91% vs 61%; P = .0004). Moreover, patients in treatment-free remission (100%) or on TKI therapy (89%) had higher survival vs patients who underwent hematopoietic stem cell transplantation (50%) or not receiving TKI treatment (33%; P < .001).

Study details: Findings are from an observational study assessing COVID-19 outcomes in 92 patients with CML in Latin America between March and December 2020.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Pagnano KB et al. Leuk Lymphoma. 2021 Jul 13. doi: 10.1080/10428194.2021.1950709.

Key clinical point: Long-term analysis indicated clear growth deceleration over time during nilotinib treatment in pediatric patients with newly diagnosed or imatinib/dasatinib resistant/intolerant Philadelphia chromosome-positive (Ph⁺) chronic myeloid leukemia (CML).

Major finding: Overall median change in height standard deviation scores after 48 cycles of nilotinib treatment vs baseline was −0.54 (range, −1.6 to 0.4) in patients resistant/intolerant to imatinib or dasatinib and −0.91 (range, −1.4 to −0.1) in patients with newly diagnosed CML. No new safety concerns were reported.

Study details: Findings are from the phase 2 DIALOG study including 58 pediatric patients with newly diagnosed (n=25) or imatinib or dasatinib resistant/intolerant (n=33) Ph⁺ CML who received at least 48 cycles of nilotinib treatment or discontinued the study.

Disclosures: This study was sponsored and funded by Novartis Pharmaceuticals Corporation. Some investigators including the lead author reported ties with Novartis.

Source: Hijiya N et al. Blood Adv. 2021 Jul 26. doi: 10.1182/bloodadvances.2020003759.

Key clinical point: Long-term analysis indicated clear growth deceleration over time during nilotinib treatment in pediatric patients with newly diagnosed or imatinib/dasatinib resistant/intolerant Philadelphia chromosome-positive (Ph⁺) chronic myeloid leukemia (CML).

Major finding: Overall median change in height standard deviation scores after 48 cycles of nilotinib treatment vs baseline was −0.54 (range, −1.6 to 0.4) in patients resistant/intolerant to imatinib or dasatinib and −0.91 (range, −1.4 to −0.1) in patients with newly diagnosed CML. No new safety concerns were reported.

Study details: Findings are from the phase 2 DIALOG study including 58 pediatric patients with newly diagnosed (n=25) or imatinib or dasatinib resistant/intolerant (n=33) Ph⁺ CML who received at least 48 cycles of nilotinib treatment or discontinued the study.

Disclosures: This study was sponsored and funded by Novartis Pharmaceuticals Corporation. Some investigators including the lead author reported ties with Novartis.

Source: Hijiya N et al. Blood Adv. 2021 Jul 26. doi: 10.1182/bloodadvances.2020003759.

Key clinical point: Long-term analysis indicated clear growth deceleration over time during nilotinib treatment in pediatric patients with newly diagnosed or imatinib/dasatinib resistant/intolerant Philadelphia chromosome-positive (Ph⁺) chronic myeloid leukemia (CML).

Major finding: Overall median change in height standard deviation scores after 48 cycles of nilotinib treatment vs baseline was −0.54 (range, −1.6 to 0.4) in patients resistant/intolerant to imatinib or dasatinib and −0.91 (range, −1.4 to −0.1) in patients with newly diagnosed CML. No new safety concerns were reported.

Study details: Findings are from the phase 2 DIALOG study including 58 pediatric patients with newly diagnosed (n=25) or imatinib or dasatinib resistant/intolerant (n=33) Ph⁺ CML who received at least 48 cycles of nilotinib treatment or discontinued the study.

Disclosures: This study was sponsored and funded by Novartis Pharmaceuticals Corporation. Some investigators including the lead author reported ties with Novartis.

Source: Hijiya N et al. Blood Adv. 2021 Jul 26. doi: 10.1182/bloodadvances.2020003759.

Key clinical point: Higher incidence of uncontrolled blood pressure (BP) was observed in patients with chronic myeloid leukemia (CML) receiving nilotinib vs imatinib or dasatinib, which may be involved in the pro-atherogenic mechanism underlying the development of cardiovascular disease in nilotinib-treated patients.

Major finding: Overall, 47.9% of patients were hypertensive and 32.9% of patients showed uncontrolled BP (at least 130/80 mmHg) on 24-hour ambulatory BP monitoring (ABPM). Patients receiving nilotinib vs dasatinib or imatinib showed a higher incidence of uncontrolled BP in ABPM (45.5% vs 20%; P = .041).

Study details: This observational study assessed clinical BP and 24-hour ambulatory BP in 73 patients with CML receiving active tyrosine kinase inhibitor treatment with either imatinib, nilotinib, or dasatinib.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Roa-Chamorro R et al. Sci Rep. 2021 Jul 19. doi: 10.1038/s41598-021-94127-2.

Key clinical point: Higher incidence of uncontrolled blood pressure (BP) was observed in patients with chronic myeloid leukemia (CML) receiving nilotinib vs imatinib or dasatinib, which may be involved in the pro-atherogenic mechanism underlying the development of cardiovascular disease in nilotinib-treated patients.

Major finding: Overall, 47.9% of patients were hypertensive and 32.9% of patients showed uncontrolled BP (at least 130/80 mmHg) on 24-hour ambulatory BP monitoring (ABPM). Patients receiving nilotinib vs dasatinib or imatinib showed a higher incidence of uncontrolled BP in ABPM (45.5% vs 20%; P = .041).

Study details: This observational study assessed clinical BP and 24-hour ambulatory BP in 73 patients with CML receiving active tyrosine kinase inhibitor treatment with either imatinib, nilotinib, or dasatinib.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Roa-Chamorro R et al. Sci Rep. 2021 Jul 19. doi: 10.1038/s41598-021-94127-2.

Key clinical point: Higher incidence of uncontrolled blood pressure (BP) was observed in patients with chronic myeloid leukemia (CML) receiving nilotinib vs imatinib or dasatinib, which may be involved in the pro-atherogenic mechanism underlying the development of cardiovascular disease in nilotinib-treated patients.

Major finding: Overall, 47.9% of patients were hypertensive and 32.9% of patients showed uncontrolled BP (at least 130/80 mmHg) on 24-hour ambulatory BP monitoring (ABPM). Patients receiving nilotinib vs dasatinib or imatinib showed a higher incidence of uncontrolled BP in ABPM (45.5% vs 20%; P = .041).

Study details: This observational study assessed clinical BP and 24-hour ambulatory BP in 73 patients with CML receiving active tyrosine kinase inhibitor treatment with either imatinib, nilotinib, or dasatinib.

Disclosures: No source of funding was identified. The authors declared no conflict of interests.

Source: Roa-Chamorro R et al. Sci Rep. 2021 Jul 19. doi: 10.1038/s41598-021-94127-2.

Key clinical point: Treatment with new-generation tyrosine kinase inhibitors (TKIs), i.e., bosutinib, nilotinib, and ponatinib, but not dasatinib, increased the risk of hepatotoxicity compared with imatinib among patients with chronic-phase chronic myeloid leukemia (CML-CP).

Major finding: Overall, patients receiving new-generation TKIs vs imatinib were at an increased risk of all-grade alanine aminotransferase (ALT) elevation (relative risk [RR], 2.89), high-grade ALT elevation (RR, 4.36), all-grade aspartate aminotransferase (AST) elevation (RR, 2.20), and high-grade AST elevation (RR, 2.65; all P < .001). Dasatinib was not associated with an increased risk of ALT or AST elevation.

Study details: Findings are from a systematic review and meta-analysis of 9 studies, including 3,475 patients with CML-CP that compared hepatotoxicity of bosutinib, dasatinib, nilotinib, and ponatinib vs imatinib.

Disclosures: This work was funded by the National Key Research and Development Program of China and the Fundamental Research Funds for the Central Universities. The authors did not report any conflict of interests.

Source: Wang Z et al. JAMA Netw Open. 2021 Jul 22. doi: 10.1001/jamanetworkopen.2021.20165.

Key clinical point: Treatment with new-generation tyrosine kinase inhibitors (TKIs), i.e., bosutinib, nilotinib, and ponatinib, but not dasatinib, increased the risk of hepatotoxicity compared with imatinib among patients with chronic-phase chronic myeloid leukemia (CML-CP).

Major finding: Overall, patients receiving new-generation TKIs vs imatinib were at an increased risk of all-grade alanine aminotransferase (ALT) elevation (relative risk [RR], 2.89), high-grade ALT elevation (RR, 4.36), all-grade aspartate aminotransferase (AST) elevation (RR, 2.20), and high-grade AST elevation (RR, 2.65; all P < .001). Dasatinib was not associated with an increased risk of ALT or AST elevation.

Study details: Findings are from a systematic review and meta-analysis of 9 studies, including 3,475 patients with CML-CP that compared hepatotoxicity of bosutinib, dasatinib, nilotinib, and ponatinib vs imatinib.

Disclosures: This work was funded by the National Key Research and Development Program of China and the Fundamental Research Funds for the Central Universities. The authors did not report any conflict of interests.

Source: Wang Z et al. JAMA Netw Open. 2021 Jul 22. doi: 10.1001/jamanetworkopen.2021.20165.

Key clinical point: Treatment with new-generation tyrosine kinase inhibitors (TKIs), i.e., bosutinib, nilotinib, and ponatinib, but not dasatinib, increased the risk of hepatotoxicity compared with imatinib among patients with chronic-phase chronic myeloid leukemia (CML-CP).

Major finding: Overall, patients receiving new-generation TKIs vs imatinib were at an increased risk of all-grade alanine aminotransferase (ALT) elevation (relative risk [RR], 2.89), high-grade ALT elevation (RR, 4.36), all-grade aspartate aminotransferase (AST) elevation (RR, 2.20), and high-grade AST elevation (RR, 2.65; all P < .001). Dasatinib was not associated with an increased risk of ALT or AST elevation.

Study details: Findings are from a systematic review and meta-analysis of 9 studies, including 3,475 patients with CML-CP that compared hepatotoxicity of bosutinib, dasatinib, nilotinib, and ponatinib vs imatinib.

Disclosures: This work was funded by the National Key Research and Development Program of China and the Fundamental Research Funds for the Central Universities. The authors did not report any conflict of interests.

Source: Wang Z et al. JAMA Netw Open. 2021 Jul 22. doi: 10.1001/jamanetworkopen.2021.20165.

The seroconversion was highest in patients with CML with 75% and observed in 5/6 (83%) of CML patients receiving imatinib that compare favorably to the total group with 58% of seroconversions. Interestingly patients treated with pegylated interferon also had a a high response with 88% (7/8).

Another recent publication by Harrington et al Br J Hem 2021, Jun 3 ahead or print, confirmed and extending the previous data by evaluating humoral and cellular immune responses after a first injection of BNT162b2 vaccine in 16 patients with CML. 87.5% patients have a seroconversion and 93.3% developed a T cell response. These responses are seen in contrast to patients with lymphoid hematological malignancies where the responses have been significantly lower.

The main goal of the treatment for chronic phase CML is to stop the progression to more advanced phased of the disease such as blast phase, where treatments are limited and there are no consensus in the treatment approach. In a recent publication by Saxena et al. J Hematol Oncol. 2021 Jun 15 the authors reported the outcomes of patients with BP-CML treated with different regimens that include a combination therapy of tyrosine kinase inhibitor (TKI) with intensive chemotherapy (IC) or hypomethylating agent (HMA) as well as  TKI or IC alone. Response rates were similar between patients treated with IC + TKI and HMA + TKI. When compared to treatment with TKI alone, treatment with IC/HMA + TKI was superior (CRi 57.5% vs 33.9%), as well as higher complete cytogenetic response rate (45% vs 10.7%) and more patients proceeding to ASCT (32.5% vs 10.7%). The results were even better when using a second generation TKI in combination with IC or HMA with a favorable EFS and OS compared to TKI alone.

The seroconversion was highest in patients with CML with 75% and observed in 5/6 (83%) of CML patients receiving imatinib that compare favorably to the total group with 58% of seroconversions. Interestingly patients treated with pegylated interferon also had a a high response with 88% (7/8).

Another recent publication by Harrington et al Br J Hem 2021, Jun 3 ahead or print, confirmed and extending the previous data by evaluating humoral and cellular immune responses after a first injection of BNT162b2 vaccine in 16 patients with CML. 87.5% patients have a seroconversion and 93.3% developed a T cell response. These responses are seen in contrast to patients with lymphoid hematological malignancies where the responses have been significantly lower.

The main goal of the treatment for chronic phase CML is to stop the progression to more advanced phased of the disease such as blast phase, where treatments are limited and there are no consensus in the treatment approach. In a recent publication by Saxena et al. J Hematol Oncol. 2021 Jun 15 the authors reported the outcomes of patients with BP-CML treated with different regimens that include a combination therapy of tyrosine kinase inhibitor (TKI) with intensive chemotherapy (IC) or hypomethylating agent (HMA) as well as  TKI or IC alone. Response rates were similar between patients treated with IC + TKI and HMA + TKI. When compared to treatment with TKI alone, treatment with IC/HMA + TKI was superior (CRi 57.5% vs 33.9%), as well as higher complete cytogenetic response rate (45% vs 10.7%) and more patients proceeding to ASCT (32.5% vs 10.7%). The results were even better when using a second generation TKI in combination with IC or HMA with a favorable EFS and OS compared to TKI alone.

The seroconversion was highest in patients with CML with 75% and observed in 5/6 (83%) of CML patients receiving imatinib that compare favorably to the total group with 58% of seroconversions. Interestingly patients treated with pegylated interferon also had a a high response with 88% (7/8).

Another recent publication by Harrington et al Br J Hem 2021, Jun 3 ahead or print, confirmed and extending the previous data by evaluating humoral and cellular immune responses after a first injection of BNT162b2 vaccine in 16 patients with CML. 87.5% patients have a seroconversion and 93.3% developed a T cell response. These responses are seen in contrast to patients with lymphoid hematological malignancies where the responses have been significantly lower.

The main goal of the treatment for chronic phase CML is to stop the progression to more advanced phased of the disease such as blast phase, where treatments are limited and there are no consensus in the treatment approach. In a recent publication by Saxena et al. J Hematol Oncol. 2021 Jun 15 the authors reported the outcomes of patients with BP-CML treated with different regimens that include a combination therapy of tyrosine kinase inhibitor (TKI) with intensive chemotherapy (IC) or hypomethylating agent (HMA) as well as  TKI or IC alone. Response rates were similar between patients treated with IC + TKI and HMA + TKI. When compared to treatment with TKI alone, treatment with IC/HMA + TKI was superior (CRi 57.5% vs 33.9%), as well as higher complete cytogenetic response rate (45% vs 10.7%) and more patients proceeding to ASCT (32.5% vs 10.7%). The results were even better when using a second generation TKI in combination with IC or HMA with a favorable EFS and OS compared to TKI alone.

Key clinical point: Patients with chronic myeloid leukemia (CML) on second-line nilotinib therapy had above-moderate quality of life (QoL) that was influenced by sex, age, education, duration of nilotinib, and existing comorbidities.

Major finding: Patients on second-line nilotinib had above-moderate global health status/QoL scores (mean, 67.70±16.80) and experienced considerable symptoms, particularly fatigue (mean, 28.28±23.74), pain (mean, 21.07±26.16), and insomnia (mean, 22.87±29.20), along with financial difficulties (mean, 52.34±32.15). Female sex (P = .017), age (P = .002), higher level of education (P = .007), duration of nilotinib usage (P = .001), and number of comorbidities (P = .024) were significantly associated with global QoL.

Study details: This study assessed QoL using the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire in 121 adult patients with CML who were resistant or intolerant to imatinib and on second-line nilotinib for at least 3 months.

Disclosures: No funding was received for this study. The authors declared no conflicts of interest.

Source: Nguyen CTT et al. Qual Life Res. 2021 Jul 14. doi: 10.1007/s11136-021-02952-9.

Key clinical point: Patients with chronic myeloid leukemia (CML) on second-line nilotinib therapy had above-moderate quality of life (QoL) that was influenced by sex, age, education, duration of nilotinib, and existing comorbidities.

Major finding: Patients on second-line nilotinib had above-moderate global health status/QoL scores (mean, 67.70±16.80) and experienced considerable symptoms, particularly fatigue (mean, 28.28±23.74), pain (mean, 21.07±26.16), and insomnia (mean, 22.87±29.20), along with financial difficulties (mean, 52.34±32.15). Female sex (P = .017), age (P = .002), higher level of education (P = .007), duration of nilotinib usage (P = .001), and number of comorbidities (P = .024) were significantly associated with global QoL.

Study details: This study assessed QoL using the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire in 121 adult patients with CML who were resistant or intolerant to imatinib and on second-line nilotinib for at least 3 months.

Disclosures: No funding was received for this study. The authors declared no conflicts of interest.

Source: Nguyen CTT et al. Qual Life Res. 2021 Jul 14. doi: 10.1007/s11136-021-02952-9.

Key clinical point: Patients with chronic myeloid leukemia (CML) on second-line nilotinib therapy had above-moderate quality of life (QoL) that was influenced by sex, age, education, duration of nilotinib, and existing comorbidities.

Major finding: Patients on second-line nilotinib had above-moderate global health status/QoL scores (mean, 67.70±16.80) and experienced considerable symptoms, particularly fatigue (mean, 28.28±23.74), pain (mean, 21.07±26.16), and insomnia (mean, 22.87±29.20), along with financial difficulties (mean, 52.34±32.15). Female sex (P = .017), age (P = .002), higher level of education (P = .007), duration of nilotinib usage (P = .001), and number of comorbidities (P = .024) were significantly associated with global QoL.

Study details: This study assessed QoL using the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire in 121 adult patients with CML who were resistant or intolerant to imatinib and on second-line nilotinib for at least 3 months.

Disclosures: No funding was received for this study. The authors declared no conflicts of interest.

Source: Nguyen CTT et al. Qual Life Res. 2021 Jul 14. doi: 10.1007/s11136-021-02952-9.

Key clinical point: Higher body mass index (BMI) and more disturbed sleep were identified as correlates of more severe fatigue, which worsen the quality of life (QoL) in patients with chronic-phase chronic myeloid leukemia (CML-CP) on tyrosine kinase inhibitor (TKI) therapy with self-reported fatigue of at least moderate severity.

Major finding: Higher BMI (P = .01) and more sleep disturbance (P less than .01) were significant correlates of more severe fatigue. Worse fatigue was associated with reduced health-related QoL (P less than .01).

Study details: This study assessed preintervention data from the CBT-TTF trial including 44 adult patients with CML-CP treated with TKIs who self-reported at least moderate fatigue.

Disclosures: This study was funded by the National Cancer Institute. HSL Jim reported consulting for RedHill BioPharma, Janssen Scientific Affairs, and Merck. Other authors declared no conflicts of interest.

Source: Oswald LB et al. Support Care Cancer. 2021 Jul 7. doi: 10.1007/s00520-021-06408-1.

Key clinical point: Higher body mass index (BMI) and more disturbed sleep were identified as correlates of more severe fatigue, which worsen the quality of life (QoL) in patients with chronic-phase chronic myeloid leukemia (CML-CP) on tyrosine kinase inhibitor (TKI) therapy with self-reported fatigue of at least moderate severity.

Major finding: Higher BMI (P = .01) and more sleep disturbance (P less than .01) were significant correlates of more severe fatigue. Worse fatigue was associated with reduced health-related QoL (P less than .01).

Study details: This study assessed preintervention data from the CBT-TTF trial including 44 adult patients with CML-CP treated with TKIs who self-reported at least moderate fatigue.

Disclosures: This study was funded by the National Cancer Institute. HSL Jim reported consulting for RedHill BioPharma, Janssen Scientific Affairs, and Merck. Other authors declared no conflicts of interest.

Source: Oswald LB et al. Support Care Cancer. 2021 Jul 7. doi: 10.1007/s00520-021-06408-1.

Key clinical point: Higher body mass index (BMI) and more disturbed sleep were identified as correlates of more severe fatigue, which worsen the quality of life (QoL) in patients with chronic-phase chronic myeloid leukemia (CML-CP) on tyrosine kinase inhibitor (TKI) therapy with self-reported fatigue of at least moderate severity.

Major finding: Higher BMI (P = .01) and more sleep disturbance (P less than .01) were significant correlates of more severe fatigue. Worse fatigue was associated with reduced health-related QoL (P less than .01).

Study details: This study assessed preintervention data from the CBT-TTF trial including 44 adult patients with CML-CP treated with TKIs who self-reported at least moderate fatigue.

Disclosures: This study was funded by the National Cancer Institute. HSL Jim reported consulting for RedHill BioPharma, Janssen Scientific Affairs, and Merck. Other authors declared no conflicts of interest.

Source: Oswald LB et al. Support Care Cancer. 2021 Jul 7. doi: 10.1007/s00520-021-06408-1.

Key clinical point: Compared with healthy controls, patients with chronic myeloid leukemia (CML) showed significantly higher expression of heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) that correlated with CML disease progression.

Major finding: HNRNPH1 mRNA expression was significantly higher in patients with CML vs healthy controls (P less than .001). HNRNPH1 expression was significantly increased in the accelerated (P less than .05) and blast (P less than .001) phase vs chronic phase of CML.

Study details: Findings are from an analysis of 60 patients with newly diagnosed, untreated CML and 30 healthy donors. Bone marrow mononuclear cells were extracted from patients, and mRNA expression was assessed using quantitative real-time polymerase chain reaction.

Disclosures: This study was partly supported by the Natural Science Foundation of Hebei Province. The authors declared no conflicts of interest.

Source: Liu M et al. Front Oncol. 2021 Jul 6. doi: 10.3389/fonc.2021.682859.

Key clinical point: Compared with healthy controls, patients with chronic myeloid leukemia (CML) showed significantly higher expression of heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) that correlated with CML disease progression.

Major finding: HNRNPH1 mRNA expression was significantly higher in patients with CML vs healthy controls (P less than .001). HNRNPH1 expression was significantly increased in the accelerated (P less than .05) and blast (P less than .001) phase vs chronic phase of CML.

Study details: Findings are from an analysis of 60 patients with newly diagnosed, untreated CML and 30 healthy donors. Bone marrow mononuclear cells were extracted from patients, and mRNA expression was assessed using quantitative real-time polymerase chain reaction.

Disclosures: This study was partly supported by the Natural Science Foundation of Hebei Province. The authors declared no conflicts of interest.

Source: Liu M et al. Front Oncol. 2021 Jul 6. doi: 10.3389/fonc.2021.682859.

Key clinical point: Compared with healthy controls, patients with chronic myeloid leukemia (CML) showed significantly higher expression of heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) that correlated with CML disease progression.

Major finding: HNRNPH1 mRNA expression was significantly higher in patients with CML vs healthy controls (P less than .001). HNRNPH1 expression was significantly increased in the accelerated (P less than .05) and blast (P less than .001) phase vs chronic phase of CML.

Study details: Findings are from an analysis of 60 patients with newly diagnosed, untreated CML and 30 healthy donors. Bone marrow mononuclear cells were extracted from patients, and mRNA expression was assessed using quantitative real-time polymerase chain reaction.

Disclosures: This study was partly supported by the Natural Science Foundation of Hebei Province. The authors declared no conflicts of interest.

Source: Liu M et al. Front Oncol. 2021 Jul 6. doi: 10.3389/fonc.2021.682859.

Key clinical point: The peripheral blood parameters of total white blood cell (WBC) count at least 20×10⁹/L, basophilia, and granulocytic left shift could help identify the need for BCR-ABL1 testing for chronic myeloid leukemia (CML) diagnosis, thereby reducing unnecessary testing, health care costs, and risk of clinically false-positive results.

Major finding: Overall, 92% of patients with newly diagnosed CML had a WBC count of at least 20×10⁹/L, whereas 92% of non-CML patients had a WBC count less than 20×10⁹/L. A positive BCR-ABL1 p210 result was associated with the presence of basophilia (86% sensitivity; 96% specificity), granulocytic left shift with circulating myelocytes and metamyelocytes (95% sensitivity; 94% specificity), and WBC of at least 20×10⁹/L (92% sensitivity; 92% specificity).

Study details: Findings are from a retrospective analysis of 495 patients undergoing first-time testing for p210 BCR-ABL1 on peripheral blood by real-time polymerase chain reaction.

Disclosures: No source of funding was identified. The authors declared no conflicts of interest.

Source: Fenu E et al. Int J Lan Hematol. 2021 Jun 29. doi: 10.1111/ijlh.13635.

Key clinical point: The peripheral blood parameters of total white blood cell (WBC) count at least 20×10⁹/L, basophilia, and granulocytic left shift could help identify the need for BCR-ABL1 testing for chronic myeloid leukemia (CML) diagnosis, thereby reducing unnecessary testing, health care costs, and risk of clinically false-positive results.

Major finding: Overall, 92% of patients with newly diagnosed CML had a WBC count of at least 20×10⁹/L, whereas 92% of non-CML patients had a WBC count less than 20×10⁹/L. A positive BCR-ABL1 p210 result was associated with the presence of basophilia (86% sensitivity; 96% specificity), granulocytic left shift with circulating myelocytes and metamyelocytes (95% sensitivity; 94% specificity), and WBC of at least 20×10⁹/L (92% sensitivity; 92% specificity).

Study details: Findings are from a retrospective analysis of 495 patients undergoing first-time testing for p210 BCR-ABL1 on peripheral blood by real-time polymerase chain reaction.

Disclosures: No source of funding was identified. The authors declared no conflicts of interest.

Source: Fenu E et al. Int J Lan Hematol. 2021 Jun 29. doi: 10.1111/ijlh.13635.

Key clinical point: The peripheral blood parameters of total white blood cell (WBC) count at least 20×10⁹/L, basophilia, and granulocytic left shift could help identify the need for BCR-ABL1 testing for chronic myeloid leukemia (CML) diagnosis, thereby reducing unnecessary testing, health care costs, and risk of clinically false-positive results.

Major finding: Overall, 92% of patients with newly diagnosed CML had a WBC count of at least 20×10⁹/L, whereas 92% of non-CML patients had a WBC count less than 20×10⁹/L. A positive BCR-ABL1 p210 result was associated with the presence of basophilia (86% sensitivity; 96% specificity), granulocytic left shift with circulating myelocytes and metamyelocytes (95% sensitivity; 94% specificity), and WBC of at least 20×10⁹/L (92% sensitivity; 92% specificity).

Study details: Findings are from a retrospective analysis of 495 patients undergoing first-time testing for p210 BCR-ABL1 on peripheral blood by real-time polymerase chain reaction.

Disclosures: No source of funding was identified. The authors declared no conflicts of interest.

Source: Fenu E et al. Int J Lan Hematol. 2021 Jun 29. doi: 10.1111/ijlh.13635.

Key clinical point: Blood cell counts collected up to 5 years before chronic myeloid leukemia (CML) diagnosis could predict BCR-ABL1 test using machine learning methods. Such predictive models may enable early diagnosis of CML, and subsequently, earlier treatment initiation, leading to a better prognosis.

Major finding: The BCR-ABL1 positivity rate was 6.2%. The ability of machine learning models to predict CML diagnosis improved with the usage of blood cell counts closer to the time of diagnosis (at diagnosis: area under the curve [AUC], 0.87-0.96; 6 months to 1-year prediagnosis: AUC, 0.75-0.80; 2-5 years prediagnosis: AUC, 0.59-0.67).

Study details: This study included 1,623 patients with a BCR-ABL1 test and at least 6 consecutive prior years of differential blood cell counts between October 1999 and April 2020 from the Veterans Health Administration database.

Disclosures: No source of funding or author disclosures were reported.

Source: Hauser RG et al. Am J Clin Pathol. 2021 Jun 29. doi: 10.1093/ajcp/aqab086.

Key clinical point: Blood cell counts collected up to 5 years before chronic myeloid leukemia (CML) diagnosis could predict BCR-ABL1 test using machine learning methods. Such predictive models may enable early diagnosis of CML, and subsequently, earlier treatment initiation, leading to a better prognosis.

Major finding: The BCR-ABL1 positivity rate was 6.2%. The ability of machine learning models to predict CML diagnosis improved with the usage of blood cell counts closer to the time of diagnosis (at diagnosis: area under the curve [AUC], 0.87-0.96; 6 months to 1-year prediagnosis: AUC, 0.75-0.80; 2-5 years prediagnosis: AUC, 0.59-0.67).

Study details: This study included 1,623 patients with a BCR-ABL1 test and at least 6 consecutive prior years of differential blood cell counts between October 1999 and April 2020 from the Veterans Health Administration database.

Disclosures: No source of funding or author disclosures were reported.

Source: Hauser RG et al. Am J Clin Pathol. 2021 Jun 29. doi: 10.1093/ajcp/aqab086.

Key clinical point: Blood cell counts collected up to 5 years before chronic myeloid leukemia (CML) diagnosis could predict BCR-ABL1 test using machine learning methods. Such predictive models may enable early diagnosis of CML, and subsequently, earlier treatment initiation, leading to a better prognosis.

Major finding: The BCR-ABL1 positivity rate was 6.2%. The ability of machine learning models to predict CML diagnosis improved with the usage of blood cell counts closer to the time of diagnosis (at diagnosis: area under the curve [AUC], 0.87-0.96; 6 months to 1-year prediagnosis: AUC, 0.75-0.80; 2-5 years prediagnosis: AUC, 0.59-0.67).

Study details: This study included 1,623 patients with a BCR-ABL1 test and at least 6 consecutive prior years of differential blood cell counts between October 1999 and April 2020 from the Veterans Health Administration database.

Disclosures: No source of funding or author disclosures were reported.

Source: Hauser RG et al. Am J Clin Pathol. 2021 Jun 29. doi: 10.1093/ajcp/aqab086.